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ABSTRACT
Introduction: Diarrhea poses a substantial
burden for patients with human
immunodeficiency virus (HIV), negatively
impacting quality-of-life (QoL) and adherence
to antiretroviral therapy. During the
combination antiretroviral therapy (cART) era,
as incidence of opportunistic infection as a
cause of diarrhea decreased, incidence of
noninfectious diarrhea (including diarrhea as
an adverse event [AE] of cART and HIV
enteropathy) increased proportionately. A
literature search was conducted for
information on prevalence, etiology, and
treatment options for noninfectious diarrhea
in patients with HIV.
Results: For marketed antiretroviral therapies,
up to 28% of patients live with [4 loose or
watery stools per day. The US Food and Drug
Administration (FDA) does not require
pharmaceutical manufacturers to include,
within approved prescribing information,
prevalence rates for all grades of diarrhea.
Traditionally, noninfectious diarrhea
management focused on avoiding use of
diarrhea-associated cART; symptom
management (nonpharmacologic and/or
pharmacologic); and, as a last resort, changing
cART. Examining the evidence upon which this
approach is based reveals that most strategies
rely upon anecdotal information and case
reports. This review summarizes the literature
and updates clinicians on the most recent
options for management of noninfectious
diarrhea in patients with HIV.
Conclusion: Diarrhea in patients with HIV is a
significant unmet clinical need that contributes
to worsening QoL and complicates medical
management. Approaching management using
a stepwise method of nonpharmacologic (diet),
nonprescription (over-the-counter) and, finally,
prescription agent changes (modification of
cART or addition of an evidence-based
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antidiarrheal) appears reasonable, despite a lack
of clear scientific evidence to support the initial
two steps of this approach. If diet modifications,
including psyllium and fiber introduction, fail
to resolve noninfectious diarrhea in patients
with HIV, loperamide followed by crofelemer
should be considered. Clinicians are encouraged
to review the most recent literature, not rely
upon prescribing information. Continued
vigilance by HIV providers to the presence of
gastrointestinal AEs, even in patients taking the
most recently approved antiretroviral agents, is
warranted. Additional research is justified in
identifying the etiology and management of
HIV-associated diarrhea in patients on
successful cART regimens.
Keywords: Antiretroviral therapy; Crofelemer;
Diarrhea; Etiology; HIV enteropathy; Loose
stools; Management; Prevalence; Loperamide
INTRODUCTION
Advances in the treatment of human
immunodeficiency virus (HIV) and acquired
immunodeficiency syndrome (AIDS) in the
past decade have changed what once was
considered a terminal illness into a
manageable chronic disease [1]. Since the
introduction of combination antiretroviral
therapy (cART) in the mid-1990s, the life
expectancy of individuals with HIV has
increased dramatically [2–4]. As a result, the
estimated number of individuals aged C13 years
living with AIDS in the United States has more
than doubled between 1996 and 2008 (219,318
vs. 479,161, respectively) [2]. Further, it is
estimated that more than 50% of patients with
HIV will be over the age of 50 years by 2015 [5].
Given the longevity achieved with current
therapeutic strategies and the increased time
patients are on these treatments because of
improved efficacy, enhancing the quality of life
(QoL) of patients with HIV by reducing
symptoms associated with HIV and its
treatment has become an important
management goal.
Diarrhea remains an important clinical
concern and is associated with reduced QoL in
individuals with HIV during cART [6–8]. For
example, diarrhea contributes to nonadherence
or justification for switching from a currently
successful cART regimen [7, 9]. While the rate of
opportunistic infections as a cause of diarrhea
has decreased in the era of cART, there has
simultaneously been a proportionate increase in
the incidence of noninfectious diarrhea, often
linked to use of antiretroviral therapy [7, 10].
Protease inhibitors (PI) and other antiretroviral
medications may alter the function of the
intestinal epithelial barrier and lead to
secretory diarrhea, leaky-flux diarrhea, or both
[11, 12]. Detrimental effects of HIV infection
itself on the gastrointestinal tract (i.e., HIV
enteropathy) constitute another noninfectious
cause of diarrhea [13]. In this review,
prevalence, etiology, and current
nonpharmacologic and pharmacologic
management of noninfectious diarrhea in
patients with HIV are described.
METHODS
A search of PubMed was conducted for general
information on prevalence, etiology, and
treatment options for noninfectious diarrhea
in patients with HIV. For treatment updates,
PubMed was searched using keywords (‘‘HIV’’
AND ‘‘diarrhea’’) OR ‘‘HIV enteropathy’’ OR
(‘‘antiretroviral’’ AND ‘‘diarrhea’’) and limited
to clinical studies published in English from
January 1995 to July 2014. To identify
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treatment updates on over-the-counter and
complementary medicines, the Natural
Medicine Comprehensive Database was
searched using the keywords ‘‘HIV and
diarrhea’’. Bibliographies from included articles
were manually reviewed for additional relevant
studies. Because of the degree of variance in
how diarrhea incidence is reported in clinical
trials, the most recent US Food and Drug
Administration (FDA)-approved prescribing
information was also reviewed for each
antiretroviral drug. Additional treatments in
development were identified by searching
ClinicalTrials.gov.
This article is a review and does not contain
any new studies with human or animal subjects
performed by any of the authors.
Prevalence of Noninfectious Diarrhea
Using observational data to determine
prevalence rates is sometimes deemed less
valuable than using data from randomized
controlled studies. However, evidence exists
that with respect to true rates of adverse
events (AEs), like noninfectious diarrhea, data
from observational studies and randomized
controlled trials are comparable [14]. In order
to facilitate reading from either viewpoint, this
review has separated observational data from
data that have been obtained from controlled
clinical studies.
Observational Studies
Before the widespread use of cART, up to 70% of
patients with HIV reported the development of
diarrhea [10, 15]. From 1995 to 1997 [7, 10, 16–
18], as the use of cART increased to [80% of
patients [19], overall rates of diarrhea decreased
but, importantly, the causality changed from
infectious to noninfectious [10]. This is reflected
in Table 1 [7, 10, 16–18]. The incidence of
opportunistic infections causing diarrhea
decreased from 53% to 13%, whereas
noninfectious causes of diarrhea increased
from 32% to 70% [10]. The predominant cause
of noninfectious cases was medication-
associated diarrhea, which increased from 0%
in 1995 to 45% in 1997. The medications most
commonly used by patients during this period
were PIs (e.g., nelfinavir, ritonavir, saquinavir,
and indinavir) and a nucleoside reverse-
transcriptase inhibitor (NRTI; didanosine) [10].
Today, despite improvement in
gastrointestinal tolerability of the newer
agents (including the one most recently
approved, dolutegravir) [20], diarrhea remains
a common condition in patients with HIV,
including those experiencing virologic and
immunologic success [7]. Two cohort studies
found diarrhea rates ranging from 39% [16] to
60% [17] and, in one instance, the incidence of
diarrhea in a population of people with HIV was
quadruple the rate reported for a non-HIV
population [7]. Considering the influence of
the class of cART, patients receiving PIs had a
higher incidence of diarrhea compared with
those on PI-sparing regimens (38% vs. 17%,
respectively) [7]. The impact on patients’ lives is
best reflected by a 2008 cross-sectional survey of
patients with HIV taking cART (n = 953), in
which diarrhea was ranked second (63.0%) only
to fatigue (70.7%) as the most common
medication-related AE [18].
Randomized Clinical Studies as Cited
in Individual cART Component Package
Inserts
The FDA does not standardize or mandate the
specific manner in which pharmaceutical
manufacturers should report diarrhea within
the approved prescribing information (also
referred to as package inserts). Table 2 outlines
the various ways in which these data are
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presented (by grade, causality, treatment
discontinuation, etc.). Package inserts
infrequently disseminate incidence rates for all
severities of diarrhea. Instead, most only report
rates using terms such as ‘‘moderate’’ and
‘‘severe’’ diarrhea, with some including the
actual percentages of patients meeting a
particular definition (e.g., [4 loose or watery
bowel movements per day). In one example,
prescribing information for the non-nucleoside
reverse-transcriptase inhibitor (NNRTI) class
only reported grade 2 or higher severity of
diarrhea using the Division of AIDS grading
scale (DIADS) definition [21], which translated
to increase from baseline of 4–6 loose or watery
bowel movements per day, poorly reflecting the
true incidence of loose stools in persons being
prescribed these agents today.
Up to 28% of patients taking today’s
commonly used antiretroviral therapies deal
with [4 loose or watery stools per day (see
Table 2) [22]. According to prescribing
Table 1 Incidence of diarrhea in observational studies
Study Study description (year) N Key results
Call et al. [10] Retrospective study of patients with HIV




Patients with opportunistic infection etiologies
decreased from 53% to 13%; patients with






Knox et al. [16] Nutrition for Healthy Living study in
inpatient, outpatient settings
(1996–1997)
671 39% of patients reported diarrheab
Zingmond et al.
[17]
2 cross-sectional cohorts: 3,745 53% of 3,745 patients reported diarrheac
HIV Cost and Service Utilization Study
(1996–1997)
2,864
Veterans Aging Cohort 3 Site Study
(1999–2000)
881
Siddiqui et al. [7] Prospective study recruiting patients in
infectious disease and primary care
clinics (2002–2003)
416 28.2% of patients with HIV vs. 7.1% in HIV-





Cross-sectional self-reported survey of
patients with HIV receiving cART
(2008)
953 63% of patients reported diarrheac as cART-
related adverse effect
cART combination antiretroviral therapy, HIV human immunodeﬁciency virus
a Diarrhea deﬁned as[3 bowel movements per day for[2 weeks
b Diarrhea deﬁned as (1) interfering with normal activity in the past month in a self-reported range of ‘‘very little or slightly’’
to ‘‘extremely’’ (severe diarrhea of C6 watery bowel movements per day), or (2) C3 loose or watery stools per day in the past
month
c Patient-reported symptom
d Diarrhea deﬁned as C3 bowel movements per day in the past 7 days
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Table 2 Incidence of diarrhea in patients with HIV for currently marketed antiretroviral therapies based on prescribing
information [22]
Drug name Diarrhea rate, % Diarrhea severity
or gradea
Multiclass combination products
Efavirenz, emtricitabine, and tenofovir disoproxil fumarate 9 Grades 2–4
Emtricitabine, rilpivirine, and tenofovir disoproxil fumarate C10 All grades
Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate 12 All grades
NRTIs
Zidovudine \5 All grades
Abacavir and lamivudine combination product 5b Grades 2–4
Abacavir 7c Grades 2–4
Abacavir, zidovudine, and lamivudine combination product 7 Grades 2–4
Tenofovir, disoproxil fumarate, and emtricitabine combination product 9b Grades 2–4
Emtricitabine C10 All grades
Tenofovir 11c Grades 2–4
Lamivudine 18 All grades
Lamivudine and zidovudine combination product 18 All grades
Didanosine 19 All grades
Stavudine 50 All grades
Enteric-coated didanosine 57d All grades
NNRTIs
Etravirine 0 Grades 2–4
Immediate release; nevirapine \1–2e Moderate to severe
Rilpivirine \2e Grades 2–4
Delavirdine 2f Moderate to severe
Efavirenz 3g Grades 2–4
Extended release; nevirapine 4h Grade C2
Protease inhibitors
Atazanavir 1–3i Moderate to severe
Indinavir 3 Moderate to severe
Saquinavir 8j Grades 2–4
Darunavir 9 h,j Grade C2
Fosamprenavir 13i,j Moderate to severe
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information, PIs demonstrate the highest
average prevalence of diarrhea (13.6%)
compared with NRTIs (10.0%, excluding
didanosine and stavudine, which are not used
commonly in clinical practice today because of
greater associated toxicities), while the average
rate of diarrhea with NNRTIs is much lower
(2.2%). Taken individually, package inserts for
the integrase inhibitors (raltegravir and
dolutegravir) and the C–C motif receptor 5
(CCR5) antagonists (maraviroc) report some of
the lowest incidences of diarrhea (B1% each
class). These figures are in contrast with a
comprehensive report using consistent DIADS-
based reporting of gastrointestinal AEs [21], in
which up to 19% of patients treated with cART
reported grades 2 through 4 diarrhea (i.e.,
moderate to potentially life-threatening
diarrhea) [23].
Protease Inhibitors Among the antiretroviral
therapy classes, diarrhea is most commonly
Table 2 continued
Drug name Diarrhea rate, % Diarrhea severity
or gradea
Tipranavir 15j Moderate to severe
(Grades 2–4)
Ritonavir 15–23 Moderate to severe
Lopinavir and ritonavir combination product 15–28i Moderate to severe
Nelﬁnavir 20k Moderate to severe
Fusion inhibitors
Enfuvirtide 32e All grades
Entry inhibitors
Maraviroc B1e All grades
Integrase inhibitors
Dolutegravir B1i Moderate to severe
Raltegravir B1h Moderate to severe
AE adverse event, NRTI nucleoside reverse-transcriptase inhibitors, NNRTI nonnucleoside reverse-transcriptase inhibitors
a Grade 1 (mild): temporary episodes of unformed stools or increase from baseline of C3 stools during a 24-h period. Grade
2 (moderate): persistent episodes of unformed to watery stools or increase from baseline of 4–6 stools during a 24-h period.
Grade 3 (severe): bloody diarrhea or increase from baseline of C7 stools during a 24-h period or intravenous ﬂuid
supplementation required. Grade 4 (potentially life-threatening): potentially fatal [23]
b With efavirenz
c With lamivudine and efavirenz
d With nelﬁnavir and stavudine
e With background regimen
f With zidovudine
g With zidovudine and lamivudine
h With tenofovir and emtricitabine
i With NRTI backbone
j Ritonavir-boosted regimen
k With stavudine and lamivudine
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associated with PIs [24]. More recently approved
agents in this class have a reportedly lower
incidence of diarrhea than older agents
(Table 2) [24–27]. The primary use of ritonavir
is as a pharmacokinetic booster for other PIs
(100 mg once daily with atazanavir or darunavir
[in treatment-naı¨ve patients with no
documented darunavir-resistant HIV
mutations]; 100 mg twice daily with lopinavir,
fosamprenavir, or darunavir [in treatment-
experienced patients with darunavir-resistant
HIV mutations]; or 200 mg twice daily with
tipranavir). Partly due to the frequency of
gastrointestinal AEs, ritonavir is rarely used
today as the sole PI (600 mg twice daily) [23].
All ritonavir-boosted PIs cause some degree of
diarrhea, but data from clinical studies reveal
differences in rates of diarrhea according to the
PI being used [28]. Lopinavir/ritonavir (10–11%)
and fosamprenavir/ritonavir (13%) cause higher
rates of drug-related moderate to severe diarrhea
in treatment-naı¨ve patients compared with
atazanavir/ritonavir (2%) and darunavir/
ritonavir (4%) therapies [25–27].
Nucleoside/Nucleotide Reverse-Transcriptase
Inhibitors It is challenging for clinicians to
understand how the NRTIs commonly used
today contribute to diarrhea rates in cART-
treated patients, as clinical studies with NRTIs
report gastrointestinal AEs inconsistently [29,
30]. In the HIV Study With Epzicom and
Truvada ([EPZ104057; ClinicalTrials.gov
identifier NCT00244712]) study of abacavir/
lamivudine versus tenofovir disoproxil
fumarate/emtricitabine (N = 688), the
incidence of grades 2–4 drug-related diarrhea
was similar in the tenofovir/emtricitabine and
abacavir/lamivudine treatment groups (19% for
both arms) in treatment-naı¨ve patients [29].
However, these patients also received
concomitant lopinavir/ritonavir, which is
individually reported to generate grade 2 or
higher diarrhea in 10–11% of patients [25, 26].
Clinicians must interpret at the patient level if
the additional 8–9% incidence of diarrhea is
attributable to the NRTI backbone or other
causes. A review of 13 studies evaluating PI-
sparing NRTI plus NNRTI cART regimens
(included NRTIs were tenofovir/emtricitabine,
tenofovir/lamivudine, or zidovudine/
lamivudine) in antiretroviral therapy–naı¨ve
patients (N = 3649) reported that up to 38%
(range 0–38%) of patients experienced diarrhea
(all definitions of diarrhea were considered)
[30].
Non-Nucleoside Reverse-Transcriptase
Inhibitors Reporting of AEs in clinical trials
with NNRTIs (first-generation [efavirenz and
nevirapine] and second-generation [etravirine
and rilpivirine]) predominantly limited
diarrhea severity data to grades 3 or 4 (or
the patient having bloody diarrhea, an
increase from baseline of C7 stools during a
24-h period, or a need for intravenous fluid
supplementation) [23]. This approach appears
to have resulted in gastrointestinal AEs to be
reported as rarely occurring. In the AIDS
Clinical Trials Group Study A5142 trial
(ClinicalTrials.gov identifier: NCT00050895)
of treatment-naı¨ve patients, the percentage of
patients reporting grade 3 or 4 diarrhea was
\1% in the treatment arm receiving efavirenz
plus 2 NRTIs and 3% in the lopinavir/ritonavir
plus efavirenz arm [31]. The apparently lower
rate of diarrhea reported for lopinavir/
ritonavir may be an artifact of authors
reporting only grade 3 or worse diarrhea
instead of grade 2 or worse and not
reflective of all grades of diarrhea
experienced in the population studied. This
supports the theory that clinicians are
challenged to know the true incidence of
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clinically meaningful diarrhea in patients due
to the lack of standardized reporting and less
inclusive FDA labeling requirements.
Notably distinct is the reporting of all grades
of diarrhea for etravirine in clinical trials. The
rate of all-grade diarrhea in adults was lower for
etravirine versus placebo (18% vs. 24%) in a
pooled 48-week analysis of the Demonstrate
Undetectable viral load in patients Experienced
with ARV Therapy studies (DUET-1 [TMC125-
C206] and DUET-2 [TMC125-C216];
ClinicalTrials.gov identifiers NCT00254046
and NCT00255099, respectively) [32]. The
lower incidence versus placebo, although
substantial, may help explain why no data on
the incidence of diarrhea in adults are reported
in the FDA-approved label.
Integrase Inhibitors In clinical trials, integrase
inhibitors (raltegravir, elvitegravir, dolutegravir)
demonstrated incidences of moderate to severe
diarrhea similar to those observed with placebo.
The raltegravir studies (Blocking Integrase in
Treatment Experienced Patients with a Novel
Compound against HIV BENCHMRCK-1 [MK-
0518] and BENCHMRCK-2 [MK-0519];
ClinicalTrials.gov identifiers NCT00293267
and NCT00293254, respectively) of patients
with treatment-resistant HIV infection
reported an *4% incidence of moderate to
severe diarrhea in both the raltegravir and
placebo groups [33]. This rate is notably
distinct from the incidence of diarrhea of all
grades, which was reported in the publication
supplement to be 18.4% in the raltegravir group
and 21.1% in the placebo group [33]. From a
clinician standpoint, while it is valuable to
know the difference in rates between arms of
the trial, having a better idea of the true
incidence that is likely to occur in patients is
also important.
Fixed-Dose Combination Antiretroviral
Products Incidence of diarrhea with fixed-
dose combination, single-tablet regimens
appears to be based on the side effect profiles
of the component medications or, at times, a
compilation of data from various studies
involving the coformulated agents and the
data used in FDA-approved package inserts.
For instance, in a 48-week phase 3 clinical trial
of efavirenz/emtricitabine/tenofovir disoproxil
fumarate, diarrhea of any grade was reported in
8% of patients [34]. However, in the prescribing
information for this formulation, the incidence
of moderate to severe diarrhea is reported as 9%
(Table 2). The publication on the phase 3,
48-week, clinical trial of elvitegravir/cobicistat/
emtricitabine/tenofovir disoproxil fumarate
reported an incidence of 22% for diarrhea of
any grade [35]. However, the incidence of all
grades of diarrhea in the approved labeling is
only 12%. This variance in incidence and
severity reporting (12% vs. 22%) reinforces the
need for individual patients prescribed this
combination agent to be assessed by their
clinicians for the occurrence of loose stools.
As summarized earlier, clinicians are likely to
face challenges when it comes to predicting the
true rates of diarrhea occurring in persons
taking cART, using only prescribing
information. Accordingly, regardless of which
combination of antiretroviral therapy is
initiated, patients should be counseled to
report loose, watery stools or diarrhea to
enable their medical providers to determine
whether the etiology of the patient’s diarrhea is
infectious (not covered in this review) or
noninfectious.
Etiology of Noninfectious Diarrhea
The etiology of noninfectious diarrhea in
patients with HIV is multifactorial and most
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likely includes (in decreasing order of influence)
cART-associated diarrhea; the detrimental
effects of HIV on the gastrointestinal tract (i.e.,
HIV enteropathy); and, infrequently, HIV-
associated malignancies and pancreatitis [36].
cART-Associated Diarrhea
There are two primary theoretical mechanisms
by which cART may cause diarrhea: damage to
the intestinal epithelial barrier, which leads to
‘‘leaky-flux’’ diarrhea, and altered secretion of
calcium-dependent chloride ions, which causes
secretory diarrhea [11, 12, 37].
Intestinal barrier damage: In in vitro and
in vivo studies, PIs induced endoplasmic
reticulum stress and activated an unfolded
protein response, leading to apoptosis of
intestinal cells [38]. Two caveats to these data
are (1) the concentrations of PIs used in these
studies substantially exceeded those obtained in
humans treated with the FDA-approved doses of
PIs [6], and (2) no substantiation of the leaky-
flux model for cART-associated diarrhea in
humans has been published.
Altered secretion of chloride ions: Secretory
diarrhea is characterized by increased secretion
of the chloride ion (Cl-) into the lumen, with
subsequent sodium and water accompaniment
[39]. Studies specifically evaluating PIs have
demonstrated induction of secretory diarrhea
via the potentiation of calcium-activated
chloride conductance [37], but published
human data supporting this concept are
limited. A botanical agent that acts as a dual
inhibitor of the cyclic adenosine
monophosphate (cAMP)-stimulated cystic
fibrosis transmembrane conductance regulator
(CFTR) chloride channel and the calcium-
activated chloride channel (CaCC) was shown
to improve symptoms of diarrhea and decrease
stool chloride concentrations in patients with
HIV receiving cART [40, 41].
HIV Enteropathy
HIV enteropathy has been proposed to result
from viral infection of gastrointestinal
enterocytes, leading to a loss of the intestinal
epithelial barrier function of the
gastrointestinal mucosa [13, 42, 43]. This loss
may manifest as villous atrophy, crypt
hyperplasia, and villous blunting, leading to
increased permeability [44]. Consequent
activation of the gastrointestinal immune
system, leading to inflammation, may further
trigger barrier degradation. Finally, a well-
described complication of HIV infection is HIV
directly damaging the autonomic nerves of the
intestine, leading to faster intestinal transit
times [6].
Implications of Noninfectious Diarrhea
in Patients with HIV
Diarrhea is known to complicate the
management of patients with HIV by
contributing to nonadherence or causing a
need for modification of an otherwise
virologically and immunologically successful
regimen [7, 9]. Especially concerning is when
patients independently decide to discontinue
cART due to diarrhea. In a retrospective study
analyzing first-line antiretroviral therapy
discontinuation during a 22-year period (1,861
patient-years of follow up), gastrointestinal
symptoms were the most common AEs
associated with treatment discontinuation [9].
Adverse event management guidelines
recommend careful evaluation of the
symptoms and symptomatic management of
AEs before switching antiretroviral therapy if
AEs are mild to moderate in severity
(particularly with diarrhea and nausea) [45]. As
has been illustrated earlier in this review,
providers are hampered in their ability to
ascertain the true rates of mild to moderate
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diarrhea for cART agents in use today. This
forces healthcare providers to potentially base
their decisions on regimen component changes
on less than optimal information [22].
Switching from one antiretroviral therapy to
another is a feasible option, although patients
who switch therapy are at an increased risk for
reduced QoL [46]. Further, there are a limited
number of times for which patients can switch
therapies before recycling of antiretroviral
agents occur [47]. Therefore, symptomatic
management of mild to moderate AEs before
switching from a successful antiretroviral
regimen may be preferable.
Management of Noninfectious Diarrhea
As a general rule, management of medical
conditions begins with lifestyle modification
followed by alteration of the offending agent (if
considered to be the etiology). When these
methods fail, clinicians then resort to available
‘‘therapies.’’ Agents selected should result from
careful consideration of input from both the
patient/caregiver and existing medical
literature. Balancing these datasets, healthcare
providers develop personal algorithms for
management, especially when clear guidance
is not available. HIV-associated diarrhea (in
patients optimally on stable, successful ART)
lacks standardized guidelines. Presented below
is a compendium of options with varying
degrees of available data and successful
outcomes. Where possible, a suggested order
of use in patients is provided.
Successful management of diarrhea in
patients with HIV has a number of important
potential benefits, including improving
adherence to cART, enabling patients to
maintain an otherwise successful regimen,
improving nutritional status, stabilizing
weight, and enhancing QoL [8, 48, 49].
Management of noninfectious diarrhea in
patients with HIV receiving cART initially
should include supportive nonpharmacologic
treatments, followed by pharmacologic
treatments, with cART modification as a
secondary option. However, limited evidence
exists for the use of nonpharmacologic and
pharmacologic approaches [49–55]. This review
focused on literature involving patients with
HIV, as cART requires special considerations.
Nonpharmacologic and Complementary
Alternative Medicine Approaches
Traditional nonpharmacologic agents for the
symptomatic treatment of diarrhea in patients
with HIV include dietary modifications, use of
fiber, and administration or application of other
supplements (see Table 3) [49, 51–55].
Dietary Modification
Unfortunately, for the evidence-driven clinician,
scientific data supporting the effectiveness of
dietary interventions for managing diarrhea in
patients with HIV are sparse. A single clinical
study of symptom management in HIV-
associated diarrhea (N = 75) using normal foods
(i.e., a low-fat, low insoluble fiber, lactose-free,
high soluble fiber, and caffeine-free diet) versus a
control group without dietary restrictions
reported that after 24 weeks, dietary
intervention was effective in reducing stool
frequency (p = 0.0003) and improving stool
consistency (p = 0.0002) [51]. This approach is
reasonable and should be encouraged. It is also
potentially a beneficial lifestyle modification for
patients with HIV, especially those with
comorbid conditions of diabetes and obesity.
Bulking Agents
Classified by the FDA as food supplements,
psyllium and oat bran are bulking agents.
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Although bulking agents are commonly
employed to remedy diarrhea, historically they
have shown limited utility in patients with HIV
and diarrhea [49, 56, 57]. Data do not exist
regarding use of bulking agents with today’s
commonly used antiretroviral agents. As an
additive or adjunct therapy with dietary
modifications, it is relatively inexpensive and
there appears little harm to attempting this
remedy, if agreeable to the patient.
Probiotics
Probiotics, often promoted to ‘‘enhance’’ the
immunologic health of the gastrointestinal
system [58, 59], have been studied in the
treatment and prevention of diarrhea in
patients with HIV. While the mechanism for
the effects of probiotics on gastrointestinal
immune health have been reported on in
more detail elsewhere, the existing evidence
for efficacy is conflicting [60]. In a randomized,
crossover, placebo-controlled study in 17 HIV-
infected patients with noninfectious diarrhea
receiving antiretroviral therapy, the majority of
whom (89%) were receiving PIs (nelfinavir or
ritonavir), therapy with the probiotic
Lactobacillus rhamnosus GG for 2 weeks did not
significantly affect the frequency or consistency
of stools compared with placebo. However, in
another randomized, double-blind, clinical
study in patients with HIV not receiving
antiretroviral therapy, probiotic yogurt
containing mixed Lactobacilli strains resolved
moderate diarrhea in all 12 patients within
2 days of treatment compared with 2 of 12
patients receiving nonprobiotic yogurt (i.e.,
control group) for 15 days [52, 61]. In a larger
placebo-controlled, randomized study, 69
patients with HIV who were also naı¨ve to
antiretroviral therapy received treatment with
Lactobacilli strains for 25 weeks but reported no
significant modification of diarrheal symptoms
compared with placebo [62]. At present, the use
of probiotics for the treatment of noninfectious
diarrhea in patients with HIV (especially those
receiving cART) is not supported in the
literature. However, the limited body of
evidence does not reflect the wide diversity of
probiotics available that have yet to be tested
and may demonstrate verifiable efficacy in the
future. This approach, similar to bulking agents,
falls into the unscientifically grounded category
of ‘‘unlikely to cause harm’’ and seems
reasonable if favored by the patient.
Table 3 Nonpharmacologic treatment for noninfectious diarrhea in patients with HIV [49, 51–55]
Agent/intervention Theorized mechanism of action
Dietary intervention Reduces caffeine, fat, and lactose intake, and increases soluble ﬁber consumption
Psyllium Increases ﬁber content and acts as a bulking agent
Oat bran Increases soluble ﬁber and acts as a bulking agent
Probiotics Modulate and normalize enteric ﬂora
Bovine serum
immunoglobulin
Restores mucosal immunity and gastrointestinal function by reducing intestinal inﬂammation




Affects gastric motility, electrical activity, and secretion of gastric acid, pancreatic enzymes, and
bile by stimulating the points along the stomach or spleen channels
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Bovine Serum-Derived Immunoglobulin
This agent is known to reduce inflammation of
the intestine, restore mucosal immunity, and
improve gastrointestinal function [63]. In a
small, open-label, 8-week study in eight
patients with HIV enteropathy, treatment with
oral serum-derived bovine immunoglobulin
reduced the median number of bowel
movements per day (5.8–2.0; p = 0.008) and
improved stool consistency, as scored on a scale
of 1 (formed) to 6 (watery) (5.3–3; p = 0.008). A
clinical trial of this agent in the treatment of
patients with HIV-associated enteropathy is
currently ongoing (ClinicalTrials.gov identifier:
NCT01828593). This approach, addressing
potentially two of the theoretical causes of
HIV enteropathy, is scientifically sound. It
shows promise, but definitive data are
pending. Bovine serum-derived
immunoglobulin is currently available as a
medical food and is FDA approved for use in
clinical dietary management of enteropathy,
including HIV-associated forms [64]. Its place
within the treatment decision algorithm should
be known following completion of ongoing
clinical trials.
L-Glutamine
In a randomized, placebo-controlled study of 25
patients with HIV and nelfinavir-induced
diarrhea, supplementation with L-glutamine
significantly reduced the severity of diarrhea.
Based on a 5-point scale for assessment of bowel
movements, with normal = grade 0 and [7
stools/day = grade 4, the mean grade of
diarrhea for patients taking L-glutamine was
0.76, compared with a mean grade of diarrhea
of 1.85 for patients who received placebo;
p\0.01 [53, 65]. However, this approach has
not been replicated by others, nor has it been
evaluated using cART agents commonly
prescribed today. Further data would be
beneficial to interpret where L-glutamine fits
into the treatment paradigm.
Curcumin
The beneficial effects of curcumin have been
reported in the treatment of various disease
states. The mechanism of action of curcumin in
diarrhea is theorized to be related to its anti-
inflammatory properties (the reader is referred
to Dulbecco and Savarino 2013 [66] for a
comprehensive review of this agent and its
potential medicinal properties). Curcumin is a
naturally occurring hydrophobic phenol
extracted from turmeric, which is best known
as the primary spice in curry or the yellowing
agent for some varieties of mustard. With
respect to HIV-associated diarrhea, there is a
single clinical study (n = 8) of patients treated
with curcumin for a mean of 41 weeks (7/8
patients were receiving cART) [54]. In this case
series of eight patients, curcumin therapy
resulted in rapid (mean 13 days) and complete
resolution of diarrhea and normalization of
stool quality. No additional studies replicating
these results with curcumin have been
published. More standardized studies of the
efficacy of curcumin as a therapeutic agent for
diarrhea are needed before curcumin treatment
can be recommended. Clinicians who wish to
consider adding it to patients’ diet as a dietary
supplement are encouraged to first formally
evaluate the balance necessary between other
dietary elements and curcumin concentration
to maintain the antidiarrheal effect of
curcumin.
Acupuncture
The combination of acupuncture and
moxibustion (application of heat generated by
burning of an herbal mixture containing
Artemisia) has been used to address the bowel
patterns of patients with HIV; however,
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evidence for the effectiveness of this therapy is
limited [55]. While many patients with HIV
may receive acupuncture to alleviate
symptoms, it would likely take a clinical
research network-generated, peer-reviewed
publication describing the antidiarrheal effect
of acupuncture and moxibustion to fully
inform practicing clinicians and patients alike
on this particular use. Until sufficient data are




Adsorbents such as bismuth subsalicylate and
attapulgite act by adsorbing fluids and
compounds to improve stool consistency (see
Table 4) [67]. This approach for managing HIV-
associated noninfectious diarrhea has been
considered based on the high degree of success
observed in some patients using adsorbents to
treat travelers’ diarrhea [68, 69]. However, the
etiology and pathophysiology of travelers’
diarrhea is distinct from that of HIV-associated
noninfectious diarrhea, and the success of
therapies for travelers’ diarrhea has not
transferred to the setting of HIV [70]. Clinical
evidence for the use of these agents in
controlling diarrhea in the HIV population is
limited to one randomized, double-blind study
that reported that attapulgite was no better
than placebo for improving stool consistency or
stool frequency in adults with HIV and diarrhea
[67, 71]. These agents cannot be recommended
for use at this time for the treatment of HIV-
associated noninfectious diarrhea.
Antimotility Agents
Oral antimotility agents such as loperamide and
diphenoxylate/atropine are opioid derivatives,
which increase fecal transit time by decreasing
bowel activity and increasing tone in the large
intestine. These actions, in turn, provide greater
opportunity for the potentially leaky
gastrointestinal tract to absorb fluid from the
gut [67].
Loperamide The best evidence for chronic use
of loperamide in patients with HIV comes from
a study that included concomitant use of
Table 4 Pharmacologic treatment for noninfectious diarrhea in patients with HIV [50, 67, 73]




Adsorbent Can cause constipation; no evidence of drug–drug
interactions with components of cART
Loperamide Antimotility agent Cramping, constipation; potential drug interaction
with numerous antiretroviral therapies; familiar to patients
Diphenoxylate/atropine Antimotility agent Abuse potential
Octreotide Antisecretory agent Potentially serious hormonal and gastrointestinal
disturbances; injectable
Crofelemer Antisecretory agent Low rate of AEs; no clinically relevant drug–drug
interactions
AE adverse event, cART combination antiretroviral therapy
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antimicrobial treatment for intestinal
infections, which does not allow for
conclusions to be drawn on loperamide
efficacy in the management of noninfectious
diarrhea [72]. A retrospective study, published
in abstract form in 1998 and cited in reviews,
indicated that 32% of patients with HIV
receiving nelfinavir responded to loperamide
treatment for the management of diarrhea [49].
However, the use of loperamide, particularly for
long-term management, may be limited by
treatment-related AEs, including drug
interactions with antiretroviral therapy [73,
74]. As a P-glycoprotein (P-gp) substrate unable
to cross the blood–brain barrier (P-gp efflux
pump prevents this translocation), loperamide
generally only possesses peripheral opioid
activity [75]. Although PIs (as P-gp inhibitors)
could increase loperamide levels in the brain,
potentially causing respiratory depression [76],
formal evaluation of coadministration of
loperamide with ritonavir-boosted tipranavir
did not result in any clinically relevant central
nervous system opioid effects [75]. Given the
substantial clinical history of use of loperamide
to treat diarrhea in patients with HIV, despite
minimal supporting peer-reviewed evidence,
loperamide represents a relatively safe and
inexpensive first-line approach.
Diphenoxylate/Atropine Data on the use of
diphenoxylate/atropine for the treatment of
diarrhea in patients with HIV are sparse. There
are anecdotal, non-peer-reviewed reports of
low-dose (1–5 mg) diphenoxylate/atropine for
the treatment of PI-induced diarrhea. However,
in one published trial of six patients previously
unresponsive to loperamide therapy, there was
no benefit with diphenoxylate/atropine [49]. In
addition, as diphenoxylate crosses the blood–
brain barrier at high doses, this potentially leads
to dependence and abuse, further discouraging
use of this product [73]. As with loperamide, the
evidence for use of diphenoxylate/atropine to
treat diarrhea in patients with HIV is primarily
anecdotal. Despite its long-standing history of
availability, this agent should be reserved for
patients unresponsive to other options, given
its propensity for AEs (including constipation
and abuse risk).
Antisecretory Agents
Octreotide and crofelemer are antisecretory
agents with peer-reviewed published data
showing their efficacy in treating diarrhea in
patients with HIV. These agents inhibit
secretory processes within the enterocyte, but
the mechanism for their effects, safety profiles,
and drug–drug and drug–disease interaction
potentials vary greatly.
Octreotide This semisynthetic analogue of
somatostatin (a key regulatory protein of the
lower gastrointestinal tract that causes slower
gastrointestinal transit times) is administered
for the symptoms of metastatic carcinoid
tumors and vasoactive intestinal peptide
secreting adenomas (both resulting in loose,
watery diarrhea) [77]. The non-depot
formulation of subcutaneously injected
octreotide has been administered for
symptomatic treatment of diarrhea in patients
with HIV; results of published studies have been
mostly positive but not limited to noninfectious
diarrhea populations [73, 78–82]. Cello et al.
[78] evaluated 51 males and females with or
without concomitant Mycobacterium,
Cryptosporidium or microsporidial infections
and refractory diarrhea. Reductions in stool
volumes of 50% or greater over 21 days were
reported when patients were treated every 8 h
with incrementally increasing doses of
octreotide [78]. In 1996, Beaugerie et al. [79]
reported a profound response from a mean ± SE
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stool frequency at baseline of 5.7 ± 1.8 to
1.3 ± 0.9 after 1 week of up to thrice daily
dosing of octreotide in 3 (23%) of the study
participants. It must be emphasized, however,
that octreotide can cause serious, severe
hormonal effects (altered balance between
insulin, glucagon, and growth hormone,
resulting in hypoglycemia and hyperglycemia),
along with gastrointestinal disturbances such as
gallbladder contractility (resulting in biliary
tract abnormalities including sludge); nausea;
abdominal discomfort; constipation; and,
paradoxically, diarrhea [77]. Equally important
is the impact that octreotide, a subcutaneously
administered agent, may have on the
absorption of orally administered agents,
including antiretrovirals. Overall, octreotide is
rarely administered in clinical practice for the
management of diarrhea in patients with HIV
and should only be considered after careful
evaluation of risk–benefit.
Crofelemer (SP-303) Crofelemer is an FDA-
approved, orally administered, minimally
absorbed, botanical drug derived from the
stem bark latex of the Croton lechleri tree [83].
Crofelemer is an inhibitor of both the cAMP-
stimulated CFTR chloride channel and the
CaCC; both of these ion channels regulate Cl-
and fluid secretion via intestinal epithelial cells
[84] and are proposed as mechanisms of
antidiarrheal action for this agent.
Pharmacokinetic data indicate minimal
systemic absorption of oral crofelemer,
irrespective of concomitant food intake or
duration of exposure [41, 83, 85]. Data from
in vitro studies have shown that there is no
cytochrome P450-mediated metabolism at
clinical concentrations of crofelemer, and no
clinically relevant drug–drug interactions with
nelfinavir, zidovudine, and lamivudine [85].
Although these antiretroviral agents are poor
representatives of antiretrovirals commonly
used today, the available published literature
reflects currently used agents (as described later)
without loss of clinical efficacy noted.
The two clinical studies published to date on
the use of crofelemer in HIV-associated, non-
infectious diarrhea have largely shown positive
results using various outcome measures
(including somewhat inconsistent and
subjective approaches) such as stool weight
and volume, patient reported improvement,
etc. [40, 41].
In the initial phase 2 (randomized, double-
blind, placebo-controlled) study in patients
with HIV-associated diarrhea (N = 51; 41/51
patients on cART and 39/41 patients on PI),
crofelemer treatment (500 mg every 6 h for
4 days) resulted in a reduction in mean stool
weight compared with placebo on day 4 (451.3
vs 150.7 g/day; p = 0.14) but only numerically
reduced the stool frequency compared with
placebo in the same time frame (3.0 vs 2.0
stools/day; p = 0.3) [40].
The second study (N = 374) demonstrated
that significantly more patients receiving
crofelemer 125 mg twice daily obtained a
reduction from an average of 2.7 watery stools
per day (*17 watery stools per week) to \2
watery stools per week for C2 of the 4-week
double-blinded, randomized treatment periods
compared with placebo (17.6% vs. 8.0%,
p = 0.01) [41]. Other outcome measures
favoring crofelemer 125 mg twice daily over
placebo were daily watery bowel movements
(-0.96 vs. -0.75; p = 0.04) and daily stool
consistency score (-0.43 vs. -0.28; p = 0.02).
A key determinant of success appears to be
patients previously failing to respond to
antidiarrheal therapy (18.1% vs. 3.5%,
p = 0.002). Duration of use in the double-blind
phase and the 20-week placebo-free extension
phase appeared to be consistent with response
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and supports the phase 2 findings of trends
toward improvement with exposure [40, 41].
The safety profile for crofelemer was
comparable to that of placebo in each dose
group. Changes from baseline in HIV clinical
parameters (i.e., HIV viral load and CD4? cell
counts) and antiretroviral adherence were
minimal, nondetrimental, and comparable
between crofelemer and placebo treatment
groups during the placebo-controlled phase.
The results from these studies suggest that
crofelemer should be considered for patients
who have failed with over-the-counter
loperamide or other antidiarrheal drugs.
Importantly, if used, patients must be
informed that the benefit is not immediate
and improves with continued use. Because
crofelemer was not formally studied in
combination with loperamide, clinicians
should use their judgement to bridge
crofelemer onset of effect (anecdotally
perceived to be *4 weeks by the primary
author) with intermittent loperamide use. This
hypothesis warrants formal investigation. Also,
it is worthwhile noting that if no benefit is seen
within 3 months, crofelemer should be
discontinued and alternatives considered.
CONCLUSIONS
Diarrhea in patients with HIV is a significant
unmet clinical need that contributes to
worsening QoL and complicates the medical
management of HIV infection. Because diarrhea
incidence is inconsistently reported in clinical
trials and package inserts of antiretroviral
agents, and because the definitions used to
generate rates of diarrhea for patients with HIV
receiving cART tend to vary, clinicians are
strongly encouraged to question all patients
on any cART about their personal experiences
with loose, watery stools. Complicating patient
management further, the availability of
published, peer-reviewed evaluations of
treatments for noninfectious diarrhea in
patients with HIV is limited. Weighing the
entirety of the available information, it
appears that if diet modifications, including
introduction of psyllium and fiber, fail to
resolve a case of confirmed noninfectious
diarrhea in patients with HIV, loperamide
followed by crofelemer should be considered.
Beyond this recommendation, the clinician is
encouraged to review the most recent literature
available, not relying upon prescribing
information. The key to success at each stage
of management is for medical professionals to
ensure that their patients’ incidences of watery
stools have been resolved within 1 month of the
start of treatment so as to avoid continuation of
ineffective therapies and decrease the likelihood
of antiretroviral discontinuation.
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